<scp>CALR</scp> mutations screening should not be studied in splanchnic vein thrombosis
Nerea Castro(Hospital Universitario 12 De Octubre), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Inmaculada Rapado(Wellcome Sanger Institute), Rosa Ayala(Hospital Universitario 12 De Octubre)
Cited by 15
Related Papers
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523